




A monthly report summarizing the Life Science transactions and trends in Washington State.


Washington State Transactions

## Washington State Transactions by Industry



## Number of Deals per Sector

\*As of 7/29/20



Monthly Highlights

### HIGHLIGHTS

- A-Alpha Bio** announced receipt of an \$800,000 grant from the Bill & Melinda Gates Foundation. This funding is to support further research on interactions between antibodies and pathogens, including the SARS-CoV-2 virus and other coronaviruses. The project will be completed in partnership with Lumen Bioscience, a Seattle-based company worked to develop antibodies delivered orally to treat gastrointestinal tract diseases. The Gates Foundation previously funded a pilot study that demonstrated the ability of A-Alpha Bio’s AlphaSeq platform to successfully screen multi-target antibodies. In this next phase, researchers will use the platform’s data to train machine learning models that can be used to create drugs to treat respiratory and intestinal diseases. A-Alpha Bio is a graduate of the WA Innovation Network Mentoring Program. ([Geekwire](#))
- Accolade** announced an initial public offering at the beginning of this month, trading under the symbol “ACCD.” This is Seattle’s first IPO of 2020. Accolades platform helps employees navigate their health benefits they receive through their employer by connecting them with on-call nurses and other clinicians as needed. ([Geekwire](#); [Accolade website](#))
- Tasso** announced closing of a \$17M investment round. Tasso’s device, Tasso OnDemand, allows users to take a blood sample in their homes and mail it to a lab versus having to visit a lab or testing site in person. Tasso is a graduate of the WA Innovation Network Mentoring Program. ([Geekwire](#))

This report is prepared by Laura Sconyers, Manager of Entrepreneurship. Questions or comments? Contact [laura@lswinstitute.org](mailto:laura@lswinstitute.org).

\*\*The data in this report are sourced from Pitchbook, Inc. and other publicly disclosed information. It is not independently verified by Life Science Washington Institute. Grants are not reported in this summary.



## Washington Life Science Transactions June 2020

<u>Date</u>	<u>Company</u>	<u>Type</u>	<u>Amount</u>	<u>Date</u>	<u>Company</u>	<u>Type</u>	<u>Amount</u>
1/23/2020	Athira Pharma	Convertible Debt	\$3,830,000	6/2/20	eDoula	Convertible Debt	\$50,000
1/29/2020	Ventec Life Systems	Equity	\$24,030,000	6/3/20	AIDA Healthcare	Convertible Debt	\$515,000
1/31/2020	Twistle	Equity	\$18,000,000	6/4/20	Kineta	Equity	\$100,000
1/31/2020	Soovu Labs	Convertible Debt	\$800,000	6/4/20	Athira Pharma	Cash	\$85,500,000
2/1/2020	ActX	Cash	\$5,900,000	6/11/20	Sana Biotechnology	Cash	\$435,000,000
2/1/2020	Inmedix	ven	undisclosed	6/12/20	MicrobiomX	Convertible Debt	\$505,000
2/1/2020	Proteios Technology	Cash	undisclosed	6/17/20	Proprio	Cash	\$23,000,000
2/11/2020	Cardiac Insight	Debt	\$8,000,000	6/22/20	Oisin Biotechnologies	Equity	\$5,090,000
2/14/2020	Bardy Diagnostics	Cash	\$12,490,000	6/24/20	Modento	Equity	\$1,000,000
2/18/2020	PharmID	Equity	\$5,000,000	7/8/2020	LumniThera	Cash	\$14,000,000
2/19/2020	CuraCloud	Cash	undisclosed	7/13/2020	Ulcer Solutions	Equity	undisclosed
2/20/2020	Lupa Bio	Convertible Debt	undisclosed	7/13/2020	Innovega	Equity	\$2,140,000
2/21/2020	AVM Biotechnology	Equity	\$2,570,000	7/21/2020	Curvafix	Equity	\$10,750,000
2/24/2020	Selkirk Pharma	Equity	\$9,050,000		Magnolia		
	Oisin	Equity	\$2,970,000	7/22/2020	Neurosciences	Equity	\$5,000,000
2/25/2020	Biotechnologies		\$3,300,000		<b>Total</b>		<b>\$2,483,467,500</b>
2/26/2020	PVP Biologics		undisclosed				
2/27/2020	WellPepper	Equity	undisclosed				
2/28/2020	Pacific Rim Outpatient Surgery Center		undisclosed				
3/1/2020	Joylux	Cash	undisclosed				
3/1/2020	LumniThera	Cash & Equity	undisclosed				
3/1/2020	Nanodropper	Cash	\$30,000				
	Silverback	Equity	\$78,500,000				
3/11/2020	Therapeutics						
	OtoNexus Medical	Equity	\$9,700,000				
3/11/2020	Technologies						
3/19/2020	Concure Oncology	Cash & Equity	\$7,750,000				
3/20/2020	Medcurity	Cash & Equity	\$737,500				
3/26/2020	Novuson Surgical	Cash & Equity	\$2,380,000				
4/1/2020	YouScript	M&A	\$79,300,000				
	Sentinel Healthcare		undisclosed				
4/1/2020	SCI Solutions	Cash	\$190,000,000				
4/2/2020	Blaze Bioscience	Cash & Equity	\$23,230,000				
4/2/2020	Rodeo Therapeutics	Equity	\$8,950,000				
4/3/2020	98point6	Cash	\$43,000,000				
	Juva for Migraine		\$500,000				
4/15/2020	SiDx	Convertible Debt	\$1,250,000				
	welcomehomehealth	Equity	\$1,500,000				
4/21/2020	.com						
	Myosana	Cash	\$1,000,000				
4/22/2020	Therapeutics						
4/26/2020	Avalyn	Cash	\$35,500,000				
5/5/2020	Kineta	Equity	\$5,000,000				
5/14/2020	LifeStance Health	Equity	\$1,200,000,000				
	Nautilus	Cash	\$76,060,000				
5/18/2020	Biotechnology						
5/21/2020	Good Therapeutics	Cash	\$22,340,000				
5/22/2020	MDMetrix	Cash	\$1,150,000				
5/22/2020	Stratos Genomics		undisclosed				
5/22/2020	Tasso	Cash	\$17,000,000				
5/27/2020	Alvaxa Biosciences		undisclosed				

This report is prepared by Laura Sconyers, Manager of Entrepreneurship. Questions or comments? Contact [laura@lswinstitute.org](mailto:laura@lswinstitute.org).

\*\*The data in this report are sourced from Pitchbook, Inc. and other publicly disclosed information. It is not independently verified by Life Science Washington Institute. Grants are not reported in this summary.